<DOC>
	<DOCNO>NCT00361140</DOCNO>
	<brief_summary>Pre-transplant conditioning include Fludarabine dose-escalated Busulfan day -6 , -5 , -4 , -3 . Daily treatment dos adjust achieve target area plasma concentration time curve ( AUC ) . Day 0 day hematopoietic progenitor cell reinfusion . Supportive care base institutional guideline . Blood sample collect dose modification base AUC level . Dose escalation proceed determine maximally tolerate level AUC evaluate potential therapeutic benefit high dose busulfan .</brief_summary>
	<brief_title>Busulfan Safety/Efficacy Conditioning Prior Hematopoietic Cell Transplantation ( HCT )</brief_title>
	<detailed_description>Patients receive anti-seizure prophylaxis begin day -7 . Pre-transplant conditioning include Fludarabine dose-escalated Busulfan day -6 , -5 , -4 , -3 . Daily treatment dos adjust achieve target AUCs ( area plasma concentration time curve ) . Day 0 day hematopoietic progenitor cell reinfusion . Supportive care base institutional guideline . In effort prevent hepatotoxicity , ursodiol give patient . During chemotherapy patient receive concurrent metronidazole , itraconazole , give acetaminophen . Blood sample collect specific time Dose 1 Dose 4 dose modification determine base desire AUC level . Doses 3 and/or 4 adjust achieve average daily Busulfan AUC 4 treatment day . Dose escalation proceed 3 dose level determine maximally tolerate level AUC evaluate potential therapeutic benefit high dose busulfan . Graft assessment , processing , characterization do per institutional guideline . Donor-recipient chimerism ( two genetically distinct type blood cell ) characterize sample obtain pre-transplant day 30+/- 7 , 90+/-7 360+/-30 post-transplant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Inclusion Criteria Recipient : HLA A , B , C , DRB1 8/8 7/8 match relate unrelated donor . HLADQ mismatch consider ie allow addition . Histologically confirm diagnosis pathologic review Diagnosis following : 1 . Acute myelogenous leukemia ( AML ) , Acute lymphoblastic leukemia ( ALL ) , NonHodgkin 's Leukemia ( NHL ) , first remission high risk relapse , refractory primary chemotherapy , first relapse ; acute biphenotypic undifferentiated leukemia also include 2 . Myelodysplastic Syndrome ( MDS ) , IPSS &gt; 1 3 . Chronic myelogenous leukemia ( CML ) , GleevecRrefractory intolerant chronic phase , beyond chronic phase morphology cytogenetics 4 . Myeloproliferative disorder , include Phnegative CML , myelofibrosis chronic myelomonocytic leukemia ( CMML ) 5 . Multiple myeloma , refractory two line therapy . 6 . Chronic lymphocytic leukemia ( CLL ) , refractory fludarabine 7 . Hodgkin 's disease , refractory primary chemotherapy first relapse 8 . Karnofsky performance status 70100 % Organ function : 1 . Pulmonary : Diffusing capacity lung carbon monoxide ( DLCO ) great 50 % 2 . Cardiac : Left ventricular ejection fraction great 45 % 3 . Renal : Creatinine clearance ( measure calculate ) equal great 50 ml/min 4 . Hepatic : Total bilirubin less equal 2 mg/dL , ( Gilbert syndrome increase indirect bilirubin allow ) ; serum transaminase less two time upper limit normal . Signed informed consent form accordance institutional policy Exclusion Criteria Recipient : Pregnant lactate woman HIV seropositive , confirm nucleic acid test ( NAT ) Active central nervous system ( CNS ) malignancy Patients current uncontrolled bacterial , viral fungal infection ( currently take medication evidence progression clinical symptom radiologic finding ) ineligible . Unfavorable psychosocial evaluation history poor compliance prescribe medical care Current use metronidazole acetominophen , unless medically necessary ; patient must discontinue use agent least 7 day prior start BusulfexR administration Prior use MylotargR ( gemtuzumab ozogamicin ) Prior Hematopoietic Cell Transplantation ( HCT ) Prior chest abdominal irradiation great 1800 cGy Presence follow comorbid condition : 1 . History myocardial infarction coronary artery disease require catheterization stent placement less six month prior enrollment . All participant history myocardial infarction coronary artery disease must clearance cardiologist enrol . 2 . Congestive heart failure ( even symptomatically control ) 3 . Peripheral vascular disease ( include intermittent claudication history bypass arterial insufficiency ) 4 . Untreated thoracic abdominal aneurysm ( 6 cm ) 5 . History cerebrovascular accident include transient ischemic attack 6 . Dementia 7 . Connective tissue/rheumatologic disorder active disease 8 . Diabetes uncontrolled medication ( include insulin ) 9 . Hemiplegia/paraplegia 10 . History prior malignancy ( exclude nonmelanoma skin cervical carcinoma curative resection ) less 5 year enrollment follow exception . Cancer treat curative intent le 5 year review casebycase basis Principal Investigator . 11 . History renal failure require renal replacement therapy ( e.g. , hemodialysis , peritoneal dialysis , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Chimerism</keyword>
	<keyword>Allogeneic stem cell transplantation ( HCT )</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Leukemia Myeloproliferative disorder ( MPD )</keyword>
	<keyword>Leukemia , Lymphocytic</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>AUC</keyword>
	<keyword>Hematologic malignancy</keyword>
</DOC>